The FGF23‐mediated effect of suppressing renal 1,25D production during CKD through activation of Cyp24a1 can have severe downstream endocrine effects, including causing hyperparathyroidism and metabolic bone disease. Here, FGF23 is linked to hyperparathyroidism.